Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases.
Fiche publication
Date publication
mai 2021
Journal
European journal of internal medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard, Pr DE CARVALHO BITTENCOURT Marcelo
Tous les auteurs :
Decker P, Moulinet T, Lopez B, Dubucquoi S, Bonnotte B, Lakomy D, Revuz S, Luc A, Bittencourt MC, Hachulla E, Jaussaud R
Lien Pubmed
Résumé
Clinical significance of anti-Ro52 antibodies in connective tissue diseases (CTD) is controversial. Anti-Ro52 antibodies might be associated with a more severe CTD phenotype, especially interstitial lung disease (ILD). The aims of this study were to evaluate ILD prevalence and severity, the prevalence of micro- or macroangiopathy and CTD-associated cancers in CTD with anti-Ro52 antibodies.
Mots clés
Anti-Ro52 antibodies, Connective tissue disease, Interstitial lung disease
Référence
Eur J Intern Med. 2021 May 7;: